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LETTERS TO THE EDITOR 
2. The premature stimulus should not (a) cause overdrive 
suppression of the sinus pacemaker; (b) change sinoatrial 
conduction time in the returning beat; or (c) shift the sinus 
pacemaker location. 
3. The anterograde and retrograde sinoatrial conduction 
times should be equal. 
Our studies in conscious animals and other in vitro studie&s 
suggest that these criteria are seldom, if ever, fulfilled. 
Therefore we would be surprised if there were a good corre- 
lation between sinoatrial conduction time measured using the 
single premature stimulus technique and sinoatrial conduc- 
tion time measured by direct recording of sinus potential. 
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CHROMONAR AND CORONARY STEAL 
Warltier and co-workersi reported that the intravenous ad- 
ministration of chromonar (Intensain@) induced coronary steal 
after acute occlusion of a peripheral branch of the left anterior 
descending coronary artery. This decreased collateral flow to 
the ischemic region and increased the extent of myocardial 
infarction. One wonders, however, whether the methods used 
were sufficient to prove these statements. 
First, the dose used (8.0 mg/kg) is two to four times larger 
than the recommended dose for animal experiments2 or 
human treatment3*4 and should have had beneficial effects on 
oxygen supply to the heart and cardiac metabolism. Second, 
after intravenous administration, chromonar is hydrolyzed 
after 10 minutes to its metabolite, the corresponding acid, 
which has a plasma half-life of 1 hour in the dog.5 Thus, 
chromonar could hardly evoke effects on the early ischemia 
because it was administered 10 minutes after the onset of li- 
gation. Furthermore, about half of the drug’s effects vanished 
1 hour after administration during the 2 hour occlusion time. 
Third, the measured endocardial collateral flow (their Table 
I) of 1.18 ml/min per g ( = 118 ml/min* 100 g) seems extremely 
high and cannot be explained either by the ventilatory or the 
preparatory conditions. However, total coronary flow ranged 
between 50 and 65 ml/min (their Fig. 2). The normal coronary 
collateral flow was reported to be an average of 12 ml/min*lOO 
g with a total coronary flow of about 55 ml/min under com- 
parable experimental conditions.6 Therefore, it seems 
doubtful that collateral flow was measured properly. Fourth, 
the reported decrease in collateral flow within the ischemic 
zones is not adequately explained. A decrease in collateral flow 
concomitant to a flow increase in the supplying epicardial 
artery (that is, the left circumflex artery) depends on (1) the 
resistance of the left circumflex artery, and (2) on the pressure 
gradient over the collateral vessels; that is, PG = 1 - (AoP - 
PCP/AoP)(AoP = aortic pressure; PCP = post-stenotic cor- 
onary arterial pressure). Unfortunately, post-stenotic coronary 
arterial pressure was not measured in the study. Because no 
significant changes in blood pressure were reported by the 
authors, and the epicardial left circumflex arterial resistance 
is negligible under vasodilation, the collateral flow indeed 
should have been at a constant level when coronary flow in the 
left circumflex artery increased because of the lack of a suf- 
ficient pressure gradient. In addition, Schaper and co-workers7 
have shown that collateral flow is redistributed during the 
ensuing hours after coronary arterial occlusion: It decreases 
in the subendocardium and increases in the subepicardium. 
The total amount of necrosis is therefore a function of the 
amount of collateral flow and how it is distributed with time. 
It seems that the “chromonar-induced” shift in collateral flow 
after occlusion of the left anterior descending artery occurred 
as a naturally occurring pathophysiologic event independent 
of the drug’s effect. 
Finally, the measured infarct size (Table III) is too small 
in the control group. A recent papers reported an infarct size 
of about 14 percent of the perfusion area of the small pe- 
ripheral left anterior descending arterial side branch after 90 
minutes of occlusion. Also, the authors did not express the area 
of necrosis relative to the area at risk of the occluded vessel 
so that the size of the artery significantly influenced the final 
infarct size. The number of animals seems to be too small to 
elucidate the naturally occurring anatomic variations in the 
left anterior descending perfusion area. 
Besides these objections, the study suggests a general 
comment. The steal phenomenon after coronary occlusion is 
a condition that cannot be compared with clinical conditions 
where the term “steal” is used to explain angina1 pain rather 
than the sequence of acute myocardial infarction. The mea- 
surement of “steal” in acute coronary occlusion is technically 
very difficult because the acute collateral flow is very 10w.~ So 
far it remains unclear whether a pure flow-induced steal plays 
an important role in the development of acute coronary oc- 
clusion or what the clinical consequences may be. 
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In summary, our study demonstrated that maximal vasodi- 
lation of the coronary vasculature by chromonar (Intensainm) 
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